Form 4: Immunome CFO Executes Stock Option Exercise and Sale

Immunome CFO Max Rosett exercised 60,000 stock options and subsequently sold the shares under a Rule 10b5-1 trading plan.

Summary

• Max Rosett, Chief Financial Officer of Immunome, Inc., exercised 60,000 stock options at a strike price of $1.05 per share.
• Following the exercise, the reporting person sold the 60,000 shares at a weighted average price of $18.23 per share.
• The transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on December 26, 2025.
• The reporting person's direct beneficial ownership of common stock stands at 54,037 shares following these transactions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was executed under a pre-established 10b5-1 plan, which is a routine financial management activity for corporate officers.

Positives

• The transaction was pre-planned under a Rule 10b5-1 trading plan, indicating the sale was not based on non-public information.
• The exercise of options demonstrates the executive's participation in the company's equity incentive programs.

Negatives

• The executive reduced their direct holdings of common stock by 60,000 shares through the sale.

Risks

• Future share price volatility may impact the value of remaining holdings.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is a standard practice for executives to manage personal liquidity and diversify portfolios, and is generally viewed as neutral by the market when pre-arranged.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is a standard corporate governance practice for executives in the biotechnology sector to avoid potential insider trading concerns.

Stakeholder Impact

• Shareholders should note the reduction in the CFO's direct equity stake, though the pre-planned nature of the sale mitigates concerns regarding insider sentiment.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Immunome, IMNM, Insider Trading, Form 4, CFO, Stock Options